Cargando…

Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease

Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Manami, Miyazawa, Ken, Tabuchi, Masako, Tanaka, Miyuki, Yoshizako, Mamoru, Minamoto, Chisato, Torii, Yasuyoshi, Tamaoka, Yusuke, Kawatani, Makoto, Osada, Hiroyuki, Maeda, Hatsuhiko, Goto, Shigemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642347/
https://www.ncbi.nlm.nih.gov/pubmed/26561427
http://dx.doi.org/10.1038/srep16510
_version_ 1782400348047015936
author Mizuno, Manami
Miyazawa, Ken
Tabuchi, Masako
Tanaka, Miyuki
Yoshizako, Mamoru
Minamoto, Chisato
Torii, Yasuyoshi
Tamaoka, Yusuke
Kawatani, Makoto
Osada, Hiroyuki
Maeda, Hatsuhiko
Goto, Shigemi
author_facet Mizuno, Manami
Miyazawa, Ken
Tabuchi, Masako
Tanaka, Miyuki
Yoshizako, Mamoru
Minamoto, Chisato
Torii, Yasuyoshi
Tamaoka, Yusuke
Kawatani, Makoto
Osada, Hiroyuki
Maeda, Hatsuhiko
Goto, Shigemi
author_sort Mizuno, Manami
collection PubMed
description Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprotegerin (OPG)-knockout mice, specifically, whether it could control osteoclasts and reduce inflammation in periodontal tissue. We examined wild-type (WT) and OPG knockout mice (OPG KO) ligated with wire around contact points on the left first and second molars. RMA was administered twice a day to half of the mice. Using micro-computed tomography, we measured the volume of alveolar bone loss between the first and second molars, and also performed histological analysis. The OPG KO RMA+ group had significantly decreased osteoclast counts, alveolar bone loss, attachment loss, and inflammatory cytokine expression 8 weeks after ligation. Thus, RMA may reduce alveolar bone loss and inflamed periodontal tissues in patients with periodontitis.
format Online
Article
Text
id pubmed-4642347
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46423472015-11-20 Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease Mizuno, Manami Miyazawa, Ken Tabuchi, Masako Tanaka, Miyuki Yoshizako, Mamoru Minamoto, Chisato Torii, Yasuyoshi Tamaoka, Yusuke Kawatani, Makoto Osada, Hiroyuki Maeda, Hatsuhiko Goto, Shigemi Sci Rep Article Chronic periodontal disease is characterized by alveolar bone loss and inflammatory changes. Reveromycin A (RMA) was recently developed and is a unique agent for inhibiting osteoclast activity. This study analysed the effects of RMA in an experimental mouse model of periodontitis involving osteoprotegerin (OPG)-knockout mice, specifically, whether it could control osteoclasts and reduce inflammation in periodontal tissue. We examined wild-type (WT) and OPG knockout mice (OPG KO) ligated with wire around contact points on the left first and second molars. RMA was administered twice a day to half of the mice. Using micro-computed tomography, we measured the volume of alveolar bone loss between the first and second molars, and also performed histological analysis. The OPG KO RMA+ group had significantly decreased osteoclast counts, alveolar bone loss, attachment loss, and inflammatory cytokine expression 8 weeks after ligation. Thus, RMA may reduce alveolar bone loss and inflamed periodontal tissues in patients with periodontitis. Nature Publishing Group 2015-11-12 /pmc/articles/PMC4642347/ /pubmed/26561427 http://dx.doi.org/10.1038/srep16510 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Mizuno, Manami
Miyazawa, Ken
Tabuchi, Masako
Tanaka, Miyuki
Yoshizako, Mamoru
Minamoto, Chisato
Torii, Yasuyoshi
Tamaoka, Yusuke
Kawatani, Makoto
Osada, Hiroyuki
Maeda, Hatsuhiko
Goto, Shigemi
Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
title Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
title_full Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
title_fullStr Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
title_full_unstemmed Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
title_short Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
title_sort reveromycin a administration prevents alveolar bone loss in osteoprotegerin knockout mice with periodontal disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642347/
https://www.ncbi.nlm.nih.gov/pubmed/26561427
http://dx.doi.org/10.1038/srep16510
work_keys_str_mv AT mizunomanami reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT miyazawaken reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT tabuchimasako reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT tanakamiyuki reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT yoshizakomamoru reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT minamotochisato reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT toriiyasuyoshi reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT tamaokayusuke reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT kawatanimakoto reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT osadahiroyuki reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT maedahatsuhiko reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease
AT gotoshigemi reveromycinaadministrationpreventsalveolarbonelossinosteoprotegerinknockoutmicewithperiodontaldisease